KaloBios Pharmaceuticals announced late Thursday that former hedge fund manager Martin Shkreli has become its chief executive officer and chairman after he led a group of investors to buy 70% of the drug developer’s outstanding shares, or as DealBreaker so eloquently put it ” Desperate Pharmaceutical Company Hits Rock Bottom, Names Martin Shkreli CEO”- The South San Francisco-based company said Shkreli will work with KalioBios’ senior management team to ensure its continued operations. Shkreli’s majority stake in KaloBios As outlined by ValueWalk, a regulatory filing with the Securities and Exchange Commission revealed that Shkreli acquired over 1.21 million shares of KaloBios Pharmaceuticals…
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe now and get 7 days free!
